Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sameh Almousa"'
Autor:
Heetanshi Jain, Ashish Kumar, Sameh Almousa, Shalini Mishra, Kendall L. Langsten, Susy Kim, Mitu Sharma, Yixin Su, Sangeeta Singh, Bethany A. Kerr, Gagan Deep
Publikováno v:
Journal of Extracellular Vesicles, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Gut microbiome dysbiosis is a major contributing factor to several pathological conditions. However, the mechanistic understanding of the communication between gut microbiota and extra‐intestinal organs remains largely elusive. Extracellul
Externí odkaz:
https://doaj.org/article/c384ce3c14284a999d77d92256aae80c
Autor:
Hesham Afify, Alia Ghoneum, Sameh Almousa, Ammar Yasser Abdulfattah, Bailey Warren, Kendall Langsten, Daniela Gonzalez, Randy Casals, Manish Bharadwaj, Steven Kridel, Neveen Said
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract Bladder cancer (BCa) is the most common malignancy of the urinary system with increasing incidence, mortality, and limited treatment options. Therefore, it is imperative to validate preclinical models that faithfully represent BCa cellular,
Externí odkaz:
https://doaj.org/article/9642edddfaa74bfa8f06a1f1d2f9bd3a
Autor:
Shalini Mishra, Ashish Kumar, Susy Kim, Yixin Su, Sangeeta Singh, Mitu Sharma, Sameh Almousa, Hilal A. Rather, Heetanshi Jain, Jingyun Lee, Cristina M. Furdui, Sarfaraz Ahmad, Carlos M. Ferrario, Henry A. Punzi, Chia-Chi Chuang, Martin Wabitsch, Stephen B. Kritchevsky, Thomas C. Register, Gagan Deep
Publikováno v:
ACS Nano.
Autor:
Christopher Livingston, Daniela Gonzalez, Bailey Warren, Ammar Yasser Abdulfattah, Alia Ghoneum, Sameh Almousa, Junjun Shu, Neveen Said, Hebatullah Abouelfadl
Publikováno v:
Semin Cancer Biol
Platinum resistance in epithelial ovarian cancer (OvCa) is rising at an alarming rate, with recurrence of chemo-resistant high grade serous OvCa (HGSC) in roughly 75 % of all patients. Additionally, HGSC has an abysmal five-year survival rate, standi
Publikováno v:
Cancer Research. 81:2495-2495
Bladder cancer (BC) is the sixth most common cancer in the United States. Approximately, 75% of BC patients present with non-muscle invasive bladder cancer (NMIBC), which is responsive to local treatment and surveillance. However, recurrence is commo